Weekly Enforcement Report: Drug Testing Fraud Dominates
Last week’s three key cases included two involving drug testing that was either medically unnecessary, or not provided at all.
Last week’s three key cases included two involving drug testing that was either medically unnecessary, or not provided at all.
Two companies settle kickback and FCA-related claims, a qui tam case is tossed, and a lab tech loses a workplace harassment case.
In an analysis of enforcement actions from the end of 2022 to early spring 2023, cases involving urine drug testing were the most prevalent.
Recent case shows that toxicology labs and drug testing remain a primary target for federal enforcement agencies.
In this month’s roundup, three cases—including two whistleblower lawsuits and one workplace discrimination case—get dismissed.